Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00887809 · OUTCOME

Overall Objective Response

Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes · Source last updated 2016-01-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
6 months

What was measured

Overall Objective Response will be evaluated in this study using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1)

Groups in this outcome

Gemcitabine, Docetaxel, Bevacizumab

Gemcitabine, Docetaxel, Bevacizumab

Gemcitabine, Docetaxel, Placebo

Gemcitabine, Docetaxel, Placebo

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Gemcitabine, Docetaxel, Bevacizumab33
Gemcitabine, Docetaxel, Placebo10

Reported measurements

Complete Response (CR)
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Gemcitabine, Docetaxel, Bevacizumab0Not reportedNot reportedNot reportedNot reported
Gemcitabine, Docetaxel, Placebo1Not reportedNot reportedNot reportedNot reported
Partial Response (PR)
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Gemcitabine, Docetaxel, Bevacizumab9Not reportedNot reportedNot reportedNot reported
Gemcitabine, Docetaxel, Placebo1Not reportedNot reportedNot reportedNot reported
Stable Disease (SD)
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Gemcitabine, Docetaxel, Bevacizumab23Not reportedNot reportedNot reportedNot reported
Gemcitabine, Docetaxel, Placebo7Not reportedNot reportedNot reportedNot reported
Progression of Disease (POD)
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Gemcitabine, Docetaxel, Bevacizumab1Not reportedNot reportedNot reportedNot reported
Gemcitabine, Docetaxel, Placebo1Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        1
    title
    Complete Response (CR)
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        9
      2. group Id
        OG001
        value
        1
    title
    Partial Response (PR)
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        23
      2. group Id
        OG001
        value
        7
    title
    Stable Disease (SD)
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        1
      2. group Id
        OG001
        value
        1
    title
    Progression of Disease (POD)
denoms
  1. counts
    1. group Id
      OG000
      value
      33
    2. group Id
      OG001
      value
      10
    units
    Participants
description
Overall Objective Response will be evaluated in this study using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1)
groups
  1. description
    Gemcitabine, Docetaxel, Bevacizumab
    id
    OG000
    title
    Gemcitabine, Docetaxel, Bevacizumab
  2. description
    Gemcitabine, Docetaxel, Placebo
    id
    OG001
    title
    Gemcitabine, Docetaxel, Placebo
param Type
NUMBER
reporting Status
POSTED
time Frame
6 months
title
Overall Objective Response
type
PRIMARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice